Key Diagnostic Testing Markets

Content

• 1. Overview
  • 1.1 Objectives
  • 1.2 Content and Scope
  • 1.3 Methodology
  • 1.4 Executive Summary
    • 1.4.1 Glucose Monitoring
    • 1.4.2 Coagulation
    • 1.4.3 Rapid Cardiac Markers
    • 1.4.4 Drugs of Abuse Screening
    • 1.4.5 Infectious Disease Testing
      • 1.4.5.1 Campylobacter
      • 1.4.5.2 Chlamydia
      • 1.4.5.3 Clostridium difficile
      • 1.4.5.4 Cryptosporidium
      • 1.4.5.5 Dengue Fever
      • 1.4.5.6 Entamoeba histolytica
      • 1.4.5.7 Giardia Species
      • 1.4.5.8 Helicobacter pylori
      • 1.4.5.9 Hepatitis Testing
      • 1.4.5.10 HIV
      • 1.4.5.11 Rapid Influenza Testing
      • 1.4.5.12 Mononucleosis
      • 1.4.5.13 Streptococcus Testing
    • 1.4.6 Cholesterol Testing
    • 1.4.7 Tumor Markers
      • 1.4.7.1 Prostate Specific Antigen (PSA) Testing
• 2. Introduction
  • 2.1 Basic Structure and Perspectives
  • 2.2 Global Diagnostic Products Industry Status and Prognosis
  • 2.3 Size, Structure and Growth of the Industry
    • 2.3.1 Current Market Size
    • 2.3.2 Market Segments
      • 2.3.2.1 Clinical Chemistry
      • 2.3.2.2 Immunoassays
      • 2.3.2.3 Nucleic Acid Arrays
      • 2.3.2.4 Coagulation Tests
      • 2.3.2.5 Critical Care Testing
  • 2.4 Trends and Forces Driving the Industry
    • 2.4.1 Global Demographics
    • 2.4.2 Healthcare Delivery and Disease Management
    • 2.4.3 Technological Innovation
  • 2.5 Alternate Site Diagnostic Testing
• 3. Market Analysis
  • 3.1 Glucose Monitoring
    • 3.1.1 Market Size
    • 3.1.2 Competitive Landscape
      • 3.1.2.1 LifeScan, Inc.
      • 3.1.2.2 Roche Diagnostics
      • 3.1.2.3 Bayer
      • 3.1.2.4 Abbott Diagnostics
      • 3.1.2.5 HemoCue
      • 3.1.2.6 Technical Chemicals & Products
      • 3.1.2.7 GDS Technology
      • 3.1.2.8 LXN Corp.
      • 3.1.2.9 Cholestech
      • 3.1.2.10 Alternate Glucose Monitoring Products
  • 3.2 Rapid Coagulation Tests
    • 3.2.1 Roche Diagnostics
    • 3.2.2 Avocet Medical
    • 3.2.3 International Technidyne Corporation
    • 3.2.4 Cardiovascular Diagnostics
    • 3.2.5 Other Companies
  • 3.3 Rapid Cardiac Markers
    • 3.3.1 The Companies
      • 3.3.1.1 Spectral Diagnostics
      • 3.3.1.2 Biosite Diagnostics
      • 3.3.1.3 Roche Diagnostics
      • 3.3.1.4 Beckman Coulter, Inc.
      • 3.3.1.5 First Medical
      • 3.3.1.6 ANI Biotech
      • 3.3.1.7 Chembio Diagnostics
      • 3.3.1.8 Abbott Diagnostics
      • 3.3.1.9 TOSOH Medics, Inc.
      • 3.3.1.10 Roche Diagnostics
      • 3.3.1.11 Bayer Diagnostics
      • 3.3.1.12 Diagnostic Products
      • 3.3.1.13 Dade Behring
    • 3.3.2 BNP Testing and Congestive Heart Failure
      • 3.3.2.1 Differential Diagnosis
      • 3.3.2.2 Staging of Heart Failure
      • 3.3.2.3 Circulating Marker of CHF
      • 3.3.2.4 Commercial Assays for BNP and NT-proBNP
      • 3.3.2.5 Clinical Applications of BNP
      • 3.3.2.6 Correlation with NYHA Classifications
      • 3.3.2.7 Correlation with LVSD
      • 3.3.2.8 Prediction of Adverse Outcomes in Acute and Chronic Heart Disease
      • 3.3.2.9 Selection and Monitoring of Therapy
      • 3.3.2.10 Summary
  • 3.4 Drugs of Abuse Screening
    • 3.4.1 Major Players
      • 3.4.1.1 Bayer Diagnostics
      • 3.4.1.2 Biosite Diagnostics
      • 3.4.1.3 Dade Behring Syva (POC Technologies)
      • 3.4.1.4 Roche Diagnostics
      • 3.4.1.5 BioScan Screening Systems, Inc.
      • 3.4.1.6 American Bio Medica Corp.
      • 3.4.1.7 Instant Diagnostics, Inc.
      • 3.4.1.8 Worldwide Medical
      • 3.4.1.9 STC Diagnostics
      • 3.4.1.10 DynaGen, Inc.
      • 3.4.1.11 Avitar Technologies
      • 3.4.1.12 Princeton BioMeditech
      • 3.4.1.13 Abbott Diagnostics
      • 3.4.1.14 Diagnostic Products
  • 3.5 Infectious Disease Testing
    • 3.5.1 Campylobacter
    • 3.5.2 Chlamydia
    • 3.5.3 Clostridium difficile
    • 3.5.4 Cryptosporidium
    • 3.5.5 Dengue Fever
    • 3.5.6 Entamoeba histolytica
    • 3.5.7 Giardia Species
    • 3.5.8 Helicobacter pylori
    • 3.5.9 Hepatitis Testing
      • 3.5.9.1 Overview
      • 3.5.9.2 Hepatitis Serologic Markers and Nucleic Acid Testing
      • 3.5.9.2.1 Hepatitis A Virus
      • 3.5.9.2.2 Hepatitis B Virus
      • 3.5.9.2.3 Hepatitis C Virus
      • 3.5.9.2.4 Hepatitis D Virus
      • 3.5.9.2.5 Hepatitis E virus
      • 3.5.9.2.6 Hepatitis B Virus/Hepatitis C Virus Viral Load and Drug Resistance
      • 3.5.9.3 Companies and Hepatitis Tests
      • 3.5.9.3.1 Home Access Health
      • 3.5.9.3.2 Orgenics
      • 3.5.9.3.3 Princeton BioMeditech Corp.
      • 3.5.9.3.4 Chembio Diagnostics
      • 3.5.9.3.5 Abbott Diagnostics
      • 3.5.9.3.6 Beckman Coulter
      • 3.5.9.2.7 Roche Diagnostics
      • 3.5.9.3.8 Bayer Diagnostics
      • 3.5.9.3.9 Diagnostic Products Corp.
      • 3.5.9.3.10 LabCorp
    • 3.5.10 HIV
      • 3.5.10.1 Blood Versus Oral Fluid/Urine Testing
      • 3.5.10.2 Life Insurance Companies and Urine Testing
      • 3.5.10.3 HIV Outside the U.S.
      • 3.5.10.4 Markets Analysis
      • 3.5.10.5 Calypte Biomedical Corp.
      • 3.5.10.6 Orgenics
      • 3.5.10.7 Princeton BioMeditech Corp.
      • 3.5.10.8 Chembio Diagnostics
      • 3.5.10.9 OraSure Technologies
      • 3.5.10.10 Ely Labs
      • 3.5.10.11 Abbott Diagnostics
      • 3.5.10.12 Beckman Coulter
      • 3.5.10.13 Bayer Diagnostics
      • 3.5.10.14 Celera Diagnostics
      • 3.5.10.15 Roche Diagnostics
      • 3.5.10.16 MedMira, Inc.
      • 3.5.10.17 Summary and Recent Developments
    • 3.5.11 Rapid Influenza Testing
    • 3.5.12 Mononucleosis
      • 3.5.12.1 Quidel
      • 3.5.12.2 Worldwide Medical
      • 3.5.12.3 Genzyme Diagnostics
      • 3.5.12.4 Wyntek Diagnostics
      • 3.5.12.5 Wampole Laboratories
      • 3.5.12.6 GenBio
      • 3.5.12.7 Other Companies in the Market
    • 3.5.13 Rubella
    • 3.5.14 Salmonella
    • 3.5.15 Shiga-Toxin E. coli
    • 3.5.16 Staphylococcus
    • 3.5.17 Streptococcus Testing
      • 3.5.17.1 Quidel
      • 3.5.17.2 Other Companies
    • 3.5.18 TB and Lyme Disease
  • 3.6 Cholesterol Testing
    • 3.6.1 Consumer Market Disposable Testing (Single-Use)
    • 3.6.2 Instrument/Disposable Strip (Multiple-Use Instruments)
    • 3.6.3 Homocysteine
    • 3.6.4 Companies in the Market
      • 3.6.4.1 Cholestech
      • 3.6.4.2 Lifestream Technologies
      • 3.6.4.3 Actimed Laboratories
      • 3.6.4.4 Drew Scientific
      • 3.6.4.5 International Medical Innovations
  • 3.7 Tumor Markers
    • 3.7.1 Market Description
    • 3.7.2 Clinical Diagnostic Serum-Based Cancer Markers
      • 3.7.2.1 Beckman Coulter
      • 3.7.2.2 Fujirebio, Inc.
      • 3.7.2.3 Abbott Diagnostics
      • 3.7.2.4 Beckman Coulter
      • 3.7.2.5 Roche Diagnostics
    • 3.7.3 PSA Testing
      • 3.7.3.1 TOSOH Medics, Inc.
      • 3.7.3.2 Bayer Diagnostics
      • 3.7.3.3 Diagnostic Products
    • 3.7.4 Other Markers
• 4. Business Trends
  • 4.1 Industry Consolidation
  • 4.2 Breadth of Product Offering
  • 4.3 Government Regulation of Medical Devices
    • 4.3.1 Importing/Exporting Medical Devices Into and Out of the U.S.
    • 4.3.2 U.K. Regulations
    • 4.3.3 EU Regulations
    • 4.3.4 Japanese Regulations
  • 4.4 Clinical Laboratory Improvement Act (CLIA)
• 5. Patient Management Trends
  • 5.1 Trends in Patient Care and Reimbursement
    • 5.1.1 A Curious System
    • 5.1.2 The Case of Tumor Markers
    • 5.1.3 Other Federal Policy Considerations
  • 5.2 Alternate Site Testing
  • 5.3 Moderators of Growth
    • 5.3.1 Quality Assurance Issues
    • 5.3.2 Political Control
    • 5.3.3 Regulatory Requirements
    • 5.3.4 Record Keeping and Data Management
    • 5.3.5 Finance
    • 5.3.6 Emergency Room Admissions and Trends
    • 5.3.7 Attitudes of Critical Care Nurses and Physicians
  • 5.4 Personnel for POC Testing
  • 5.5 Locations of POC for Patient Care
  • 5.6 Focused Testing
  • 5.7 Satellite Facilities
  • 5.8 POC Testing
  • 5.9 Hospital Labs
  • 5.10 Doctor's Office Testing
  • 5.11 Home Care
  • 5.12 Non-traditional Collection for Sample Testing
• 6. Technology Trends
  • 6.1 Sensor Systems for Diagnostic Applications
  • 6.2 Glucose Measurements
    • 6.2.1 Different Types of Diabetes
    • 6.2.2 Public Health Impact of Diabetes
    • 6.2.3 Diagnosis of Diabetes
    • 6.2.4 Hypoglycemia
    • 6.2.5 Glucose Test Methods
  • 6.3 Cholesterol Testing
  • 6.4 The New Paradigm
  • 6.5 Consolidated Workstations and Modularity
  • 6.6 Automation and Robotics
  • 6.7 Laboratory Information Systems (LIS)
  • 6.8 Biosensor Technology
    • 6.8.1 Microfluidic and Biosensor Chip Technology
  • 6.9 Protein Sequencing
  • 6.10 DNA Sequencing
  • 6.11 The Human Genome Project
  • 6.12 Liquid Phase Chromatography
  • 6.13 Polymerase Chain Reaction
  • 6.14 Capillary Electrophoresis
  • 6.15 Proteomics
• 7. Data Management Issues
  • 7.1 Wireless Local Area Networks
  • 7.2 Wireless Technology
  • 7.3 Wireless Devices
  • 7.4 Considerations
  • 7.5 Hospital Costs of Information Management
  • 7.6 Other Information Processing Capabilities
• 8. Competitive Assessment of High-Growth Markets
  • 8.1 Glucose Monitoring
    • 8.1.1 Overview of Market Segment
    • 8.1.2 Competitive Strategies
    • 8.1.3 Analyses of the Current Market Conditions, Competition and Product Mix
    • 8.1.4 New Approaches to the Glucose Data Management Marketplace
    • 8.1.5 How Each Company is Losing/Gaining Market Share
    • 8.1.6 Partnering Opportunities with Complementary Third-Party Products
    • 8.1.7 Adjacent Markets
  • 8.2 Tumor Markers
    • 8.2.1 Overview of Market Segment
    • 8.2.2 Competitive Strategies
    • 8.2.3 Analyses of the Current Market Conditions, Competition and Product Mix
    • 8.2.4 Adjacent Markets
  • 8.3 Cardiac Care
  • 8.4 Infectious Disease
    • 8.4.1 Overview of Market Segment
    • 8.4.2 Competitive Strategies
    • 8.4.3 Analyses of the Current Market Conditions, Competition and Product Mix
    • 8.4.4 New Approaches to the Infectious Disease Marketplace
    • 8.4.5 The Impact of Molecular Diagnostic Methods on the Diagnosis of Infectious Disease
    • 8.4.6 Partnering Opportunities with Complementary Third-Party Products
    • 8.4.7 Emerging Viral Infections
  • 8.5 Coagulation
  • 8.6 Drugs of Abuse Testing/Therapeutic Drug Monitoring
• 9. Market Trends and Forecasts
  • 9.1 Home Care Analysis
  • 9.2 Non-traditional Collection for POC Testing
  • 9.3 New Systems for Critical Care and Near-Patient Testing
  • 9.4 Utility of Near-Patient Testing in Critical Care Settings
  • 9.5 Mergers of Diagnostic Companies
  • 9.6 Information Management Advances
  • 9.7 Test Ordering Patterns
  • 9.8 Patient Satisfaction
  • 9.9 Move Away from Central Laboratory
  • 9.10 Healthcare Cost Controls
  • 9.11 Future of POC Testing
  • 9.12 Biotechnology Industry Trends
  • 9.13 Pharmaceutical Industry Trends
  • 9.14 Acquisition, License Agreement, Partnerships
• 10. Corporate Profiles
  • 10.1 LabCorp
  • 10.2 Lifescan, Inc.
  • 10.3 OraSure Technologies, Inc.
    • 10.3.1 OraSure Collection Device
    • 10.3.2 OraQuick Rapid Test
    • 10.3.3 UPT
    • 10.3.4 Histofreezer
    • 10.3.5 Immunoassay Tests and Reagents
  • 10.4 Bayer Corp.
    • 10.4.1 Background
    • 10.4.2 Business Analysis
  • 10.5 MediSense
  • 10.6 i-STAT Corp.
  • 10.7 Nova Biomedical
    • 10.7.1 Introduction
    • 10.7.2 Electrolyte and Blood Gas Analyzers
    • 10.7.3 Business Analysis
  • 10.8 Wyntek Diagnostics
  • 10.9 Savyon Diagnostics
  • 10.10 Spectral Diagnostics
  • 10.11 Biosite Diagnostics
  • 10.12 Abbott Laboratories
    • 10.12.1 Background
    • 10.12.2 Key Opportunities in Rapid Tests
    • 10.12.3 Business Analysis
  • 10.13 Wampole Laboratories
  • 10.14 Beckman Coulter Diagnostics Corp.
  • 10.15 Instrumentation Laboratory
  • 10.16 MedMira Laboratories
  • 10.17 Radiometer
    • 10.17.1 Background
    • 10.17.2 Instrumentation
    • 10.17.3 Business Analysis
  • 10.18 GenBio
  • 10.19 Ely labs
  • 10.20 Orgenics
  • 10.21 bioMrieux Vitek, Inc.
  • 10.22 ANI Biotech
  • 10.23 Sybron International Corp.
  • 10.24 Optical Sensors, Inc.
  • 10.25 Worldwide Medical Corp.
  • 10.26 International Medical Innovations (IMI)
  • 10.27 Cardiovascular Diagnostics
  • 10.28 Abaxis, Inc.
  • 10.29 Inverness Medical Innovations
    • 10.29.1 Consumer Products
    • 10.29.2 Clinical Diagnostic Products
  • 10.30 ChemTrak, Inc.
    • 10.30.1 The AccuMeter Cassette System
    • 10.30.2 The Home Test Service
    • 10.30.3 Parent's Alert Home Drug Test Service
    • 10.30.4 CholesTrak Home Cholesterol Test
    • 10.30.5 Sales and Marketing
    • 10.30.6 Competition
  • 10.31 Cholestech
    • 10.31.1 Diagnostic Products
    • 10.31.2 WellCheck
  • 10.32 HemoCue, Inc.
  • 10.33 Binax Corp.
  • 10.34 Selfcare
  • 10.35 Johnson & Johnson
  • 10.36 Accumetrics
  • 10.37 First Medical, Inc.
  • 10.38 Response Biomedical Corp.
  • 10.39 Compucyte Corp.
  • 10.40 Caliper Technologies
  • 10.41 Princeton BioMeditech
  • 10.42 American Biogenics Sciences
  • 10.43 New Horizons Diagnostics
  • 10.44 Beacon Diagnostics
  • 10.45 Saliva Diagnostics
  • 10.46 Calypte Biomedical Corp.
    • 10.46.1 The Calypte Urine-Based HIV-1 Screening and Supplemental Tests
    • 10.46.2 The Cambridge Biotech Serum-Based HIV-1 Supplemental Test
    • 10.46.3 The Sentinel Testing Service
    • 10.46.4 HIV Viral Lysate Stock
  • 10.47 Meridian Diagnostic
  • 10.48 Quidel
  • 10.49 Biomerica
  • 10.50 Diagnology, Inc.
  • 10.51 BioStar (Thermo Electron Corp.)
  • 10.52 ActiMed Diagnostics
  • 10.53 Empyrean Diagnostics
  • 10.54 STC Technologies
  • 10.55 Trinity Diagnostics
  • 10.56 Genzyme Diagnostics
  • 10.57 ImmunoScience, Inc.
  • 10.58 Cygnus Therapeutic Systems
    • 10.58.1 The GlucoWatch System
    • 10.58.2 GlucoWatch G2 Biographer
    • 10.58.3 Partnerships
  • 10.59 Seradyn Clinical Diagnostics/Apogent Technologies
  • 10.60 Adeza Biomedical Corp.
  • 10.61 Array Medical
  • 10.62 Transmedica
  • 10.63 BioScan Screening Systems, Inc.
  • 10.64 American Bio Medica Corp.
  • 10.65 GDS Technology
  • 10.66 Home Access Health Corp.
  • 10.67 Pharmatech Corp.
  • 10.68 Thoratec/International Technidyne Corp.
  • 10.69 SpectRx, Inc.
  • 10.70 Helena Laboratories
  • 10.71 Technical Chemicals & Products
  • 10.72 Roche Diagnostics
  • 10.73 Simplex Medical Systems
  • 10.74 Biex, Inc.
  • 10.75 POC Technologies
  • 10.76 LXN Corp. (Inverness Medical Technologies)
  • 10.77 American Biogenetic Sciences, Inc.
  • 10.78 Lifestream Technologies
  • 10.79 PanBio Corp.
  • 10.80 Phillips Medical Systems
  • 10.81 Jiangnan Biotech
  • 10.82 MiniMed
  • 10.83 Meretek Corp.
  • 10.84 Avox Systems
  • 10.85 Dade Behring
  • 10.86 Chongqing Sungene Pharmaceutical Co., Ltd.
  • 10.87 Medical Services International, Inc.
  • 10.88 Therasense, Inc.
  • 10.89 PharmaNetics, Inc.
  • 10.90 Shanghai SIIC Kehua Biotech Co., Ltd. (Kehua Biotech)
  • 10.91 LifePoint, Inc.
  • 10.92 Avitar, Inc.
  • 10.93 Cozart Biosciences
  • 10.94 Enterix, Inc.
  • 10.95 Kyowa Medex Co., Ltd.
  • 10.96 Iatron
  • 10.97 Denka Seiken Co., Ltd.
  • 10.98 Accurex Biomedical, Pvt., Ltd.
• 11. Corporate Directory
• Index Of Figures
  • Figure 1: Serological and Clinical Course of Acute HBV Infection
  • Figure 2: Time Course of Serologic Markers in Acute Hepatitis C Infection
• Index Of Tables
  • Table 1: Ten Largest Diagnostic Companies Worldwide Revenues and Market Share 2000
  • Table 2: Total Clinical Diagnostics Dollar Volume by Market Segment 2000
  • Table 3: U.S. Market for Clinical Chemistry Dollar Volume by Analyte 2000
  • Table 4: Worldwide Market for Clinical Chemistry Dollar Volume by Analyte 2000
  • Table 5: Worldwide Market for Other Immunoassays Dollar Volume by Analyte 2000
  • Table 6: Worldwide Market for Nucleic Acid Assays for Infectious Disease Dollar Volume by Analyte 2000
  • Table 7: Worldwide Market for Other Nucleic Acid Arrays Dollar Volume by Analyte 2000
  • Table 8: Market for Coagulation Tests Dollar Volume by Region 2000
  • Table 9: Market for Critical Care Tests Dollar Volume by Region 2000
  • Table 10: U.S. Alternate Site Diagnostic Test Dollar Volume by Sector
  • Table 11: U.S. Clinical Diagnostic POC Testing and Rapid Test Market Segments Dollar Volume
  • Table 12: Number of Sites by Type Doing In Vitro Diagnostic Testing in the U.S.
  • Table 13: U.S. Clinical Laboratory Testing Services Revenue and Growth Rates by Segment
  • Table 14: U.S. Doctor's Office Test Market Revenue and Growth Rate by Segment
  • Table 15: U.S. Clinical Diagnostic Home Test Market Revenue and Growth Rates by Segments 1999
  • Table 16: U.S. In Vitro Diagnostic Testing Including Reagents, Instruments, Consumables and Controls Total Sales by Segments 1999
  • Table 17: Global Diabetic Population 1995 and 2025
  • Table 18: Worldwide POC Glucose Testing Market Dollar Volume and Growth Rate
  • Table 19: U.S. Market for POC and Near-Patient Blood Glucose Testing Market Share by Company
  • Table 20: World Market Share of POC Glucose Monitoring Marketers
  • Table 21a: Worldwide Market for Rapid Coagulation Testing Dollar Volume 2000-2008
  • Table 21b: U.S. Market for Rapid Coagulation Testing Dollar Volume 2000-2008
  • Table 21c: U.S. Market for Rapid Coagulation POC Testing Dollar Volume 1996-2007
  • Table 22: U.S. Market for POC Cardiac Marker Testing Dollar Volume and Growth Rate 1999-2007
  • Table 23: Drugs of Abuse Screening U.S. Market Size 1998-2007
  • Table 24: National Institute on Drug Abuse Screening Standards Cutoff Levels by Drug and Test Method
  • Table 25: U.S. POC Drugs of Abuse Testing Market 2001-2007
  • Table 26: Serological Diagnosis of Hepatitis B Virus Infections
  • Table 27: Lower Detection Limits of HBV DNA Assays
  • Table 28: U.S. and Global Market for HAV Diagnostic Testing
  • Table 29: U.S. and Global Market for HBV Diagnostic Testing
  • Table 30: U.S. and Global Market for HCV Diagnostic Testing
  • Table 31: Current Assays for HIV Viral Load Testing
  • Table 32: U.S. and World Markets for HIV Diagnostic Testing
  • Table 33: U.S. Cholesterol Testing Volume 2000-2007
  • Table 34: Worldwide Market for In Vitro Cancer Marker Products Dollar Volume in 1999 and 2007
  • Table 35: U.S. Market for Tumor Marker Assays Dollar Volume by Marker 1998-2002
  • Table 36: Comparison of Costs at Moderately Complex and Waived CLIA Labs
  • Table 37: CPT Codes and Reimbursement Amount for Selected Tumor Markers New York and California
  • Table 38a: POC Testing Versus Laboratory Testing Clinical Outcomes in Diabetic Ketoacidosis
  • Table 38b: POC Testing Versus Laboratory Testing Clinical Outcomes in ABG Measurements
  • Table 39: Emergency Room Admissions in the U.S.
  • Table 40: POC Testing Cost Analysis with Labor Included
  • Table 41: Cost Analysis for Glucose Testing: POCT versus Central Lab
  • Table 42: Normal Blood Glucose Values in Fasting State and Two Hours Postprandially
  • Table 43: Applications for Wireless LAN Technology Present and Future
  • Table 44: Wireless Hospital Network Access Points Technology Prices Access Points
  • Table 45: Wireless Hospital Network Access Points Technology Prices Desktop Adapters (One Computer)
  • Table 46: Wireless Hospital Network Access Points Technology Prices PCMCIA Adapters